Company Overview
Entera Bio is a clinical-stage leader developing oral peptide therapies, specifically focusing on its N-Tab® platform. Its lead candidate, EB613, is an oral bone-building tablet for osteoporosis. The company also collaborates with OPKO on programs for hypoparathyroidism and metabolic diseases.
Key Financial Figures
For the year ended December 31, 2025, Entera reported revenue of $42,000. The net loss was $11.4 million, resulting in a loss per share (EPS) of $0.25. Total operating expenses rose to $11.5 million from $9.6 million in 2024.
Additional Financial Insights
Cash and equivalents totaled $14.9 million, including $7.8 million in restricted funds. This liquidity is expected to support operations through the middle of Q3 2026. R&D expenses increased to $6.0 million due to Phase 3 preparations.